City of Industry, CA—AIDP collaborated with Nutrasource Pharmaceutical and Nutraceutical Services, a contract research organization, to achieve pre-market approval for prebiotic claims on PreticX xylooligosaccharide (XOS), according to a press release. AIDP is working to expand internationally the regulatory approval for PreticX; the company worked with Nutrasource to develop a strategic regulatory pathway for the ingredient in Canada.
The releases notes that other XOS materials, produced via different processes, result in different and distinct compositions, benefits, and dosages. Claims can only be made from human clinical studies completed on a specific XOS. PreticX has over 12 published human studies, and is the only prebiotic ingredient with novel claims.
Dr. Jennifer Gu, VP of R&D for AIDP, said in the release: “AIDP is committed to investing in unique products like PreticX. Only PreticX XOS can make the desired claims, which separates this unique product from other XOS prebiotics on the market. Working with the Nutrasource team was a collaborative effort achieved by joining their regulatory expertise with our science.”
Related: AIDP Appointed Exclusive U.S. Partner for BIOHM FX
AIDP Exclusive Distributor in North America for Natural Remedies
Gelymar Makes AIDP Its Distributor Partner in North America for Carrageenan Products
William Rowe, president and CEO of Nutrasource, said in the release: “The Nutrasource team thrives on providing novel and unique regulatory solutions for its clients. We are honored to have secured these favourable regulatory results on behalf of AIDP for Canadian market access.”